Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SQUIBB NEUROVUE NDA FILING TARGETED FOR FIRST QUARTER, 1989

Executive Summary

SQUIBB NEUROVUE NDA FILING TARGETED FOR FIRST QUARTER, 1989, Squibb reported at a securities analysts meeting Nov. 10 in Princeton, N.J. The brain imaging agent is being studied for detecting signs of dementia and mood disorders, as well as other cerebral imaging uses. Neurovue will compete against Medi-Physics' Spectamine, which was launched earlier this year, Amersham's Ceretec, now pending at FDA (see related story), and DuPont's Neurolite, which is still in clinicals. Nuerovue will complement Squibb's growing line of imaging agents, which is led by Isovue, a nonionic contrast medium. Squibb is predicting Isovue sales in 1988 will top $150 mil. Approved in December 1985, Isovue has grown into Squibb's second largest product behind Capoten. Isovue sales have climbed steeply since the product's first full year on the market in 1986, when it generated sales of $43 mil. Last year, Isovue sales more than doubled to $105 mil. For the first nine months of this year, Isovue generated sales of $113 mil. Isovue's importance to the company is highlighted in a recent Squibb publication, which points out the product's linchpin role in a broad, cross-category agreement with a managed care operation. Squibb noted that the 90-hospital Premier Hospitals Alliance recently approached the firm for a bid on contrast media. Squibb responded by offering two multi-year agreements: a five-year contrast media agreement "worth $6-8 mil." in the first year; and a three-year agreement on multiple source items. Squibb maintains that it did not cut its Isovue price to keep Premier's business. However, the managed care group benefits from savings on the multisource products and an associated bonus program based on volume. In addition, Squibb has several other imaging agents nearing the end of the pipeline. An NDA for the radiopharmaceutical Cardiotec (formerly SQ 30,217) will be submitted before year-end, Squibb predicted. The company has tested the product for use in myocardial infarction and ischemia. Squibb is also developing a gadolinium compound, SQ 30,626, for use with magnetic resonance (MRI) imaging. An NDA for that product is expected to be filed in 1991, Squibb told the analysts.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS014704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel